AccuDava has developed a molecular process to improve the efficacy of personalizing cancer chemotherapy - effectively enabling physicians to avoid ineffective drugs and select suitable treatments, based on a patientâs tumor molecular characteristics. The firm's technology is based on the identification of two âCell Surface Glycan Biomarkersâ : Glycans beingthe dynamic molecules involved in cell signaling -- the front line of cell communication and defense. Specificlally the AccuDava Biomarker is on the cell surface not within the cell and is a carbohydrate motif, not genomic or pr
